NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
Check out other big names from the same industry as NEO.
Frequently Asked Questions
The current price of NEO is 9.62 USD — it has increased by 0.74% in the past 24 hours. Watch NeoGenomics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange NeoGenomics, Inc. stocks are traded under the ticker NEO.
NEO stock has fallen by −2.87% compared to the previous week, the month change is a −14.59% fall, over the last year NeoGenomics, Inc. has showed a −36.46% decrease.
We've gathered analysts' opinions on NeoGenomics, Inc. future price: according to them, NEO price has a max estimate of 26.00 USD and a min estimate of 15.00 USD. Watch NEO chart and read a more detailed NeoGenomics, Inc. stock forecast: see what analysts think of NeoGenomics, Inc. and suggest that you do with its stocks.
NEO reached its all-time high on Dec 3, 1999 with the price of 225.00 USD, and its all-time low was 0.04 USD and was reached on Apr 16, 2003. View more price dynamics on NEO chart. See other stocks reaching their highest and lowest prices.
NEO stock is 7.23% volatile and has beta coefficient of 1.21. Track NeoGenomics, Inc. stock price on the chart and check out the list of the most volatile stocks — is NeoGenomics, Inc. there?
Today NeoGenomics, Inc. has the market capitalization of 1.22 B, it has decreased by −9.56% over the last week.
NeoGenomics, Inc. is going to release the next earnings report on May 6, 2025. Keep track of upcoming events with our Earnings Calendar.
NEO earnings for the last quarter are 0.04 USD per share, whereas the estimation was 0.03 USD resulting in a 38.73% surprise. The estimated earnings for the next quarter are −0.01 USD per share. See more details about NeoGenomics, Inc. earnings.
NeoGenomics, Inc. revenue for the last quarter amounts to 172.00 M USD, despite the estimated figure of 173.19 M USD. In the next quarter, revenue is expected to reach 171.63 M USD.
NEO net income for the last quarter is −15.32 M USD, while the quarter before that showed −17.70 M USD of net income which accounts for 13.42% change. Track more NeoGenomics, Inc. financial stats to get the full picture.
No, NEO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 29, 2025, the company has 2.2 K employees. See our rating of the largest employees — is NeoGenomics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NeoGenomics, Inc. EBITDA is −11.50 M USD, and current EBITDA margin is 0.13%. See more stats in NeoGenomics, Inc. financial statements.
Like other stocks, NEO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NeoGenomics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NeoGenomics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NeoGenomics, Inc. stock shows the strong sell signal. See more of NeoGenomics, Inc. technicals for a more comprehensive analysis. If you're still not sure, try looking for inspiration in our curated watchlists.